Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography

This study has been completed.
Sponsor:
Information provided by:
Korea University Guro Hospital
ClinicalTrials.gov Identifier:
NCT01139827
First received: June 8, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted
  Purpose

Framingham risk score is well known screening tool that detect cardiovascular (CV) risk. But it is not suitable for CV risk in mild risk group. So 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a new imaging technique for detecting vascular inflammation within atherosclerotic plaques and hsCRP is also arising detection tool of CV risk.

The investigators are examining this association in normal and impaired glucose tolerance patients groups.


Condition
Cardiovascular Risk

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional

Further study details as provided by Korea University Guro Hospital:

Enrollment: 178
Study Start Date: September 2009
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
normal
normal group has no diabetes.
IGT
IGT group has impaired fasting glucose or impaired glucose tolerance.

Detailed Description:

We examined vascular inflammation using FDG-PET scan in 178 subjects (Normal and impaired glucose tolerance groups). Vascular 18F-FDG uptake was measured as both the mean and maximum blood-normalized standardized uptake value (SUV), known as the target-to-background ratio (TBR). And We analyzed that the association with Framingham risk score, hs CRP and vascular inflammation by FDG-PET scan.

  Eligibility

Ages Eligible for Study:   16 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The subjects underwent routine health checkups at Korea University Guro Hospital. Patients with DM or gestational diabetes were not included.

Criteria

Inclusion Criteria:

  • healthy subjects

Exclusion Criteria:

  • a history of cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization)
  • active inflammatory disease, recent active infection
  • stage 2 hypertension (resting blood pressure, ≥ 160/100 mmHg)
  • diabetes mellitus
  • systemic disorders such as severe hepatic, renal, and hematologic diseases
  • taking drugs known to interfere with vascular inflammation measured by FDG-PET.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01139827

Locations
Korea, Republic of
Korea university guro hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University Guro Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01139827     History of Changes
Other Study ID Numbers: PET(FRS-CRP)
Study First Received: June 8, 2010
Last Updated: June 8, 2010
Health Authority: Korea: Institutional Review Board

Keywords provided by Korea University Guro Hospital:
atherosclerosis
inflammation
hsCRP
Framingham risk score
positron emission tomography
inflammation in FDG-PET

Additional relevant MeSH terms:
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on November 20, 2014